CIGB-258 Uses, Dosage, Side Effects and more
CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant. As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens (RPCEC00000313).
Trade Name | CIGB-258 |
Generic | CIGB-258 peptide |
CIGB-258 peptide Other Names | CIGB-258 |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |